BioSpace News Archive

NANOBIOTIX (Paris:NANO) (Euronext: NANO - ISIN: FR0011341205 – the “Company”), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the investigation of NBTXR3 activated by radiation therapy, with or without cetuximab,

Can-Fite BioPharma Ltd.(NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced the pricing of a public offering of 3,333,334 units at a price to the public of $1.50 per unit.

Therap’s health tracking features give provider agencies a range tools to efficiently track health data and visualize the data with a variety of detailed reports.

Diverse Biotech, Inc. www.diversebiotech.com has announced it has been selected to present at the upcoming BIO CEO & Investor Conference in New York on February 11th.

Border Therapy Services and Alliance Physical Therapy Partners is pleased to announce the opening of their new outpatient rehabilitation clinic located at 3330 Rinconada Blvd.

Fluidigm Corporation announced that it will establish a new Center of Excellence for Imaging Mass Cytometry™ at Georgetown Lombardi Comprehensive Cancer Center, an NCI-designated Comprehensive Cancer Center in Washington, DC.

I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders, today announced that the underwriters of the Company’s initial public offering

Guardant Health, Inc. (Nasdaq: GH) today announced it will report financial results for the fourth quarter and full year 2019 after market close on Monday, February 24, 2020.

Fluidigm Corporation announced financial results for the fourth quarter and full year ended December 31, 2019.

LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on the Investigational New Drug (IND) submission for LB-001 for the treatment of methylmalonic acidemia (MMA) pending the resolution of certain clinical and nonclinical questions.